RBM10 Regulates Tumor Apoptosis, Proliferation, and Metastasis

Yingshu Cao, Xin Di, Qinghua Zhang, Ranwei Li, Ke WangFrontiers in Oncology 2021 · DOI

Abstract

The RNA-binding motif protein 10 (RBM10) is a critical factor in alternative splicing and post-transcriptional mRNA modification. While frequently downregulated in lung, breast, and colorectal cancers, its role is complex. RBM10 typically functions as a tumor suppressor by inhibiting proliferation, promoting apoptosis, and curbing invasion and metastasis. These effects are mediated through the regulation of the MDM2-p53 negative feedback loop, apoptotic proteins like Bcl-2 and Bax, and the Notch and RAP1/AKT/CREB signaling pathways. However, emerging evidence suggests RBM10 can also exhibit oncogenic properties in specific contexts. This review synthesizes current research on RBM10’s molecular mechanisms and clinical value to provide a clearer perspective on its opposing biological effects.

Introduction

Cancer progression is often characterized by the "miswiring" of gene expression, frequently stemming from defects in alternative splicing. This process allows a single gene to produce multiple protein isoforms with distinct, sometimes opposing, functions. RNA-binding proteins (RBPs) serve as the primary regulators of this splicing landscape. Among these, RBM10 has emerged as a critical "conductor" whose dysregulation is linked to various malignancies.

Molecular Structure and Variants

RBM10 is a complex protein featuring several functional domains, including two RNA recognition motifs (RRM1 and RRM2), two zinc finger (ZnF) domains, an OCRE domain, and a G-patch. These structures enable RBM10 to interact specifically with pre-mRNA and other splicing factors to regulate exon selection.

A key feature of RBM10 is its existence in multiple isoforms, primarily variants v1 and v2. These variants differ in their inclusion of specific exons, such as exon 4, which may dictate their functional roles in the cell. Structural comparisons with its homolog RBM5 reveal shared domains but distinct regulatory behaviors across different cancer types.

Molecular structure of the RBM10 protein and structural differences between RBM5 and RBM10 variants.

Mechanisms of Tumor Suppression

RBM10 primarily functions as a tumor suppressor through several well-defined molecular pathways:

  • The Splicing "Switch": RBM10 controls the alternative splicing of critical genes. For instance, it promotes the exclusion of exon 9 in the Numb gene. This exclusion inhibits the Notch signaling pathway, a major driver of uncontrolled cell proliferation.
  • Stabilizing the "Guardian of the Genome": RBM10 promotes apoptosis by regulating the MDM2-p53 negative feedback loop. By interfering with MDM2-mediated degradation of p53, RBM10 ensures that p53 remains active to induce programmed cell death in damaged cells.
  • Pathway Inhibition: RBM10 has been shown to inhibit the RAP1/AKT/CREB pathway, which is vital for tumor invasion and metastasis across various tissue types.
  • Self-Regulation: RBM10 can bind to its own pre-mRNA to induce "nonsense-mediated decay," acting as an internal thermostat to prevent over-expression.

The Oncogenic Paradox

While its role as a suppressor is well-documented, recent evidence suggests RBM10 may exhibit oncogenic properties. This "dual identity" might be linked to the ratio of its variants; for example, variant v1 may promote proliferation while v2 promotes apoptosis. Additionally, post-translational modifications play a role. The protein C-Src can phosphorylate RBM10, causing it to translocate from the nucleus to the cytoplasm, potentially altering its function from a splicing regulator to a pro-metastatic factor.

Clinical Implications and Survival Analysis

Bioinformatic analyses using the GEPIA (Gene Expression Profiling Interactive Analysis) database have demonstrated that high expression of RBM10 and its homolog RBM5 is significantly correlated with better overall survival in major cancers, including breast invasive carcinoma (BRCA) and lung adenocarcinoma (LUAD).

In clinical cohorts, RBM10 mutations—particularly in exon 10—have been identified as independent prognostic factors for lung adenocarcinoma. These mutations typically lead to a significant decrease in RBM10 protein levels, removing a critical brake on tumor growth.

Conclusion and Future Directions

RBM10 is a multifaceted regulator of the cancer transcriptome. However, the exact conditions under which it switches from a tumor suppressor to an oncogene remain a subject of ongoing research. Future studies must distinguish between RBM10v1 and RBM10v2 to improve diagnostic accuracy. Furthermore, while RBM10 is a clear therapeutic target, no drugs currently exist to specifically modulate its activity. Developing strategies to "calibrate" RBM10 expression or function represents a promising frontier in precision oncology.

Summary updated

Abstract

The RNA-binding motif protein 10 (RBM10) is involved in alternative splicing and modifies mRNA post-transcriptionally. RBM10 is abnormally expressed in the lung, breast, and colorectal cancer, female genital tumors, osteosarcoma, and other malignant tumors. It can inhibit proliferation, promote apoptosis, and inhibit invasion and metastasis. RBM10 has long been considered a tumor suppressor because it promotes apoptosis through the regulation of the MDM2-p53 negative feedback loop, Bcl-2, Bax, and other apoptotic proteins and inhibits proliferation through the Notch signaling and rap1a/Akt/CREB pathways. However, it has been recently demonstrated that RBM10 can also promote cancer. Given these different views, it is necessary to summarize the research progress of RBM10 in various fields to reasonably analyze the underlying molecular mechanisms, and provide new ideas and directions for the clinical research of RBM10 in various cancer types. In this review, we provide a new perspective on the reasons for these opposing effects on cancer biology, molecular mechanisms, research progress, and clinical value of RBM10.
BibTeX
@inproceedings{cao2021rbm,
  author = {Yingshu Cao and Xin Di and Qinghua Zhang and Ranwei Li and Ke Wang},
  title = {{RBM10 Regulates Tumor Apoptosis, Proliferation, and Metastasis}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.603932},
}
Figure